Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022 This panel featured Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio, and Louise Gunter.

Please provide your email address to receive an email when new articles are posted on . An FDA panel voted that for adults with uncontrolled hypertension, the benefits of an ultrasound renal ...

Please provide your email address to receive an email when new articles are posted on . An FDA panel voted that for adults with uncontrolled hypertension, the benefits of a radiofrequency renal ...

Over a two-day-long FDA meeting, an agency panel of advisors considered dueling proposals for new renal denervation therapies—ultimately handing a thumbs-up to Otsuka’s ReCor Medical division, while ...

This panel was moderated by Kristie L. Kahl and featured Dr. Thomas Hutson, Louise Gunter and Meryl Uranga. Kahl: I want to shift gears to talk about side effects and dose reductions. So Louise, I ...

A radiofrequency-based renal denervation system for uncontrolled hypertension got a cool reception from FDA advisors who nevertheless left the door open for regulatory approval. On Wednesday, the ...

The US Food and Drug Administration's (FDA's) Circulatory System Devices Panel unanimously agreed that the Symplicity Spyral Renal Denervation System (Medtronic, Inc.) is safe, but the panel was split ...

Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Genetics and Epidemiology at Joslin Diabetes Center in Boston, MA. To facilitate translational research on ...

Yale School of Medicine researchers have identified a biomarker panel that improves the assessment of chronic kidney disease (CKD) progression in children. Their findings are published in the Journal ...

Medtronic suffered yet another disappointment in its relentless pursuit of bringing renal denervation to market for people living with uncontrolled high blood pressure. There seems to be no question ...

The Paradise ultrasound renal denervation system got backing from the FDA's Circulatory System Devices Panel as a possible treatment for hypertension, as manufacturer ReCor continues to hope for ...

General laboratory evaluation. Typical post-transplant monitoring labs are shown in Table 2. KDIGO suggests (with low evidence of support) that labs be obtained two to three times per week for weeks 2 ...